Application of Physiologically Based Pharmacokinetic (PBPK) Modeling to Support Dose Selection: Report of an FDA Public Workshop on PBPK.

作者: C Wagner , P Zhao , Y Pan , V Hsu , J Grillo

DOI: 10.1002/PSP4.33

关键词:

摘要: The US Food and Drug Administration (FDA) public workshop, entitled “Application of Physiologically-based Pharmacokinetic (PBPK) Modeling to Support Dose Selection focused on the role PBPK in drug development regulation. Representatives from industry, academia, regulatory agencies discussed issues within plenary panel discussions. This report summarizes discussions provides current perspectives application different areas, including its utility, predictive performance, reporting for submissions.

参考文章(5)
M d L T Vieira, M-J Kim, S Apparaju, V Sinha, I Zineh, S-M Huang, P Zhao, PBPK Model Describes the Effects of Comedication and Genetic Polymorphism on Systemic Exposure of Drugs That Undergo Multiple Clearance Pathways Clinical Pharmacology & Therapeutics. ,vol. 95, pp. 550- 557 ,(2014) , 10.1038/CLPT.2014.43
Christian Wagner, Yuzhuo Pan, Vicky Hsu, Joseph A. Grillo, Lei Zhang, Kellie S. Reynolds, Vikram Sinha, Ping Zhao, Predicting the Effect of Cytochrome P450 Inhibitors on Substrate Drugs: Analysis of Physiologically Based Pharmacokinetic Modeling Submissions to the US Food and Drug Administration Clinical Pharmacokinetics. ,vol. 54, pp. 117- 127 ,(2015) , 10.1007/S40262-014-0188-4
HM Jones, Y Chen, C Gibson, T Heimbach, N Parrott, SA Peters, J Snoeys, VV Upreti, M Zheng, SD Hall, Physiologically based pharmacokinetic modeling in drug discovery and development: a pharmaceutical industry perspective. Clinical Pharmacology & Therapeutics. ,vol. 97, pp. 247- 262 ,(2015) , 10.1002/CPT.37
David Shlaes, A Pharmaceutical Industry Perspective 42nd Annual Meeting. ,(2004)